Introduction The gastrointestinal tract functions as a highly integrated system where digestion, immunity, and metabolic regulation are closely linked to the gut microbiota. This vast microbial ecosystem plays a central role in maintaining mucosal integrity, immune balance, and systemic homeostasis.
Introduction
The gastrointestinal tract functions as a highly integrated system where digestion, immunity, and metabolic regulation are closely linked to the gut microbiota. This vast microbial ecosystem plays a central role in maintaining mucosal integrity, immune balance, and systemic homeostasis. A key emerging regulator in this interaction is the inflammasome, a multiprotein complex that senses microbial and cellular danger signals and orchestrates innate immune responses. The microbiota–inflammasome axis has recently gained attention as a crucial bridge connecting gut health with systemic diseases, including cancer, metabolic disorders, and neurological conditions.
Problem Statement
Despite growing recognition of the microbiota’s role in disease, the precise mechanisms through which dysbiosis triggers pathological immune activation remain incompletely understood. In particular, the role of inflammasomes as central mediators of microbiota-driven inflammation is underexplored. This gap limits our ability to translate microbiome science into targeted therapies, especially in complex diseases such as inflammatory bowel disease, gastrointestinal cancers, and neuroinflammatory disorders.
Summary
This review highlights that dysbiosis can aberrantly activate inflammasomes, disrupting gut homeostasis and promoting chronic inflammation. The microbiota–inflammasome axis influences not only gastrointestinal diseases but also systemic conditions via pathways such as the gut–brain axis, including vagal signaling and neuroendocrine responses. Importantly, inflammasome-mediated cytokines act as key messengers linking gut-derived signals to distant organs. Emerging evidence also demonstrates a role in cancer progression and immune modulation. The integration of artificial intelligence is accelerating understanding of these complex interactions, enabling biomarker discovery and therapeutic targeting. Overall, the microbiota–inflammasome axis represents a promising frontier for precision medicine across gastrointestinal and systemic diseases.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.